Higher BST2 Expression Promotes the Anti‐HBV Effect of IFN ‐α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg ‐Positive Chronic Hepatitis B Patients
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Jiaxuan Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Guangdong Institute of Liver Diseases, Departme…. Hauptthemen laut MEDLINE: Hepatitis B virus, Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
We previously reported that an interferon (IFN)‐inducible protein, BST2, was regulated by the JAK–STAT pathway activated by CD40, and subsequently suppressing hepatitis B virus (HBV) repliaction and transcription. The current research attempted to assess the impact of BST2 on the IFN‐treated anti‐HBV effect, and explore BST2 variants for predicting pegylated IFN alpha (PegIFNα) therapy response of patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B (CHB). Using an HBV‐transfected cell model, the function of BST2 on HBV DNA replication and transcription driven by IFN was studied. The potentially functional BST2 variants were selected through a strategy of gene‐wide screening. The associations of BST2 variants and polygenic score (PGS) model, which was used to quantify the combined influence of several genetic variants, with treatment response were examined in 2 separate PegIFNα‐treated cohorts of 238 and 707 patients with CHB, respectively. We found that overexpression of BST2 improved the anti‐HBV activity triggered by IFN‐α. Among PegIFNα‐treated patients with CHB, BST2 _rs9576 was screened out to be significantly correlated with combined response (CR; i.e., HBeAg seroconversion along with HBV DNA level
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, South…
- The Key Laboratory of Molecular Pathology (Hepatic Diseases) of Guangxi, Department of Pathology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
- Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
ORCID-Profile: Jiaxuan Chen, Jia Hou, Rong Na, Bin Zhou, Jinlin Hou, De-Ke Jiang
Zitieren
APA
Chen, J., Hou, J., Na, R., Zhou, B., Hou, J., & Jiang, D. K. (2024). Higher BST2 Expression Promotes the Anti‐HBV Effect of IFN ‐α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg ‐Positive Chronic Hepatitis B Patients. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3120
Vancouver
Chen J, Hou J, Na R, Zhou B, Hou J, Jiang DK. Higher BST2 Expression Promotes the Anti‐HBV Effect of IFN ‐α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg ‐Positive Chronic Hepatitis B Patients. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3120
BibTeX
@article{Chen2024,
author = {Chen, Jiaxuan and Hou, Jia and Na, Rong and Zhou, Bin and Hou, Jinlin and Jiang, De-Ke},
title = {Higher BST2 Expression Promotes the Anti‐HBV Effect of IFN ‐α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg ‐Positive Chronic Hepatitis B Patients},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3120}
}
EUVIMED